Clinical trial Recruiting at 1 site Phase 4 Interventional Ages 18 to 79

Evaluating Xeomin® for improving mobility after stroke

Official title: Upper Extremity Injection of Xeomin® and Changes in Gait Related Mobility in Adults After Stroke

Run by Wake Forest University Health Sciences · NCT04908423 · Data updated 2026-11-12

This study is testing if Xeomin® injections can help improve walking and movement in adults who have weakness on one side after a stroke.

Quick facts

PhasePhase 4
Study typeInterventional
Ages18 Years to 79 Years
SexAll
Enrollment20 (estimated)
SponsorWake Forest University Health Sciences
Academic / other
Locations1 site (Charlotte, North Carolina)
StatusRecruiting
StartedOctober 19, 2021
Main results expectedApril 2028
Study endsApril 2028
Registry record updatedOctober 26, 2026
Trial IDNCT04908423 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are ambulatory adults with hemiparesis and spasticity due to stroke who can walk at least 10 meters independently.

Probably not a fit

Patients with significant joint restrictions, uncorrected hearing impairments, or other neurological conditions may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This pilot study aims to assess the impact of Xeomin® injections on gait-related mobility in adult patients with hemiparesis following a stroke. Participants will undergo standardized physical function tests, including the 10-meter walk test and the timed 'up and go' test, before and 4-6 weeks after receiving the injection. The study will utilize a one-group pretest-post-test design to measure changes in mobility and will follow up with participants approximately 12 weeks post-injection to monitor any adverse events and therapeutic duration. The overall duration of the study is planned for 2 years to facilitate adequate screening, recruitment, and follow-up.

Why it matters

Potential benefit: If successful, this study could lead to improved mobility and quality of life for stroke survivors experiencing hemiparesis.

How similar studies have gone: While similar approaches have been explored, this specific application of Xeomin® for gait improvement post-stroke is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Diagnosis of hemiparesis and spasticity secondary to stroke with upper and lower limb spasticity and unilateral motor and/or sensory deficit
* No prior surgery to the lower limb
* Able to walk at least 10 meters without physical assistance from another person and without an assistive device
* Toe- ground clearance during swing phase without assistive device or orthoses
* No treatment with botulinum toxin within the past 4 months

Exclusion Criteria:

* Passive range of motion at either the ankle, knee, or elbow joint less than 30 degrees
* Participants with uncorrected hearing impairment
* Weight bearing restrictions due to concurrent orthopedic injuries that would make ambulating with or without an assistive device unsafe
* Speech language expression deficit (e.g., aphasia)
* Absence of proprioception upon neurologic examination
* Presence of fixed contractures in the upper or lower extremities not correctable to neutral
* Other confounding neurological diagnoses or active acute illness (cancer, Parkinson's disease, multiple sclerosis)

Where it's running

  • Carolinas Rehabilitation
    Charlotte, North Carolina, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.